MALT Lymhoma - Pipeline Insight, 2021

MALT Lymhoma - Pipeline Insight, 2021

  • February 2021 •
  • 60 pages •
  • Report ID: 6022121 •
  • Format: PDF
“Mucosa-associated Lymphoid Tissue (MALT) Lymphoma – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Understanding

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview
MALT lymphoma (MALToma) is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT), frequently of the stomach, but virtually any mucosal site can be affected. It is a cancer originating from B cells in the marginal zone of the MALT, and is also called extranodal marginal zone B cell lymphoma.MALT lymphoma is called extranodal because it starts in tissues or organs outside of the lymph nodes. MALT lymphomas are low-grade lymphomas. They grow slowly and remain confined to one organ for a relatively long time.They are more common in older adults but may occur in individuals in their twenties and thirties. MALT lymphomas are associated with a bacterial infection. MALT lymphomas are first classified into different stages, ranging from stage I to stage IV based on how extensive they are: Stage I: cancer is present in only one organ, Stage II: Cancer is found in two or more groups of lymph nodes on the same side of the body with respect to the diaphragm, Stage III: disease is present in lymph node groups on both sides of the diaphragm, occasionally with the involvement of other adjacent organs, Stage IV: if the liver, the bone marrow, or the lungs become involved, the disease is in stage IV.

"Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape is provided which includes the disease overview and Mucosa-associated Lymphoid Tissue (MALT) Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mucosa-associated Lymphoid Tissue (MALT) Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
? The companies and academics are working to assess challenges and seek opportunities that could influence Mucosa-associated Lymphoid Tissue (MALT) Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs Chapters
This segment of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs
• LOXO305: Loxo Oncology Inc.
LOXO-305 is an investigational, novel, selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells known as B-cells and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, mantle cell lymphoma and marginal zone lymphoma. LOXO-305 is currently being studied in a global Phase 1/2 clinical trial.

• IGM2323: IGM Biosciences Inc.
IGM-2323 is a CD20 x CD3 bispecific IgM antibody in phase I designed to treat patients with B cell Non-Hodgkin’s lymphoma (NHL) and all other B cell malignancies. CD20 is a protein that is commonly expressed on the surface of malignant B cells, while CD3 is a protein that is expressed on the surface of T cells and is an essential activating molecule of the T cell. IGM-2323 is designed to simultaneously and stably bind a CD20 expressing cancer cell as well as CD3 on a cytotoxic T cell, bringing both cells into close proximity. This interaction mimics the normal T cell activation pathway leading the T cell to recognize and kill the cancer cell by releasing cytotoxic biochemicals (perforins and granzymes) that penetrate and perforate the cancer cell.
Further product details are provided in the report……..

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
? Major Players in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
There are approx. 10+ key companies which are developing the therapies for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. The companies which have their Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drug candidates in the most advanced stage, i.e. phase I/II include, Loxo Oncology Inc.

? Phases
report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II and phase I/II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

? Route of Administration
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
? Molecule Type

Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
? Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Insights
• Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs?
• How many Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mucosa-associated Lymphoid Tissue (MALT) Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Loxo Oncology Inc.
• IGM Biosceinces Inc.
• ArQule
• Celldex Therapeutics
• TG Therapeutics, Inc.
• Beijing InnoCare Pharma Tech Co., Ltd.

Key Products
• ARQ531
• CDX1140
• IGM2323
• LOXO-305
• ICP-022
• YY-20394